About the Company
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VRCA News
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears ...
Verrica Pharmaceuticals Inc VRCA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Fourth Quarter and Year End 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is ...
Verrica Pharmaceuticals Set to Discuss Q4 and Full-Year 2023 Financial Results in Upcoming Conference Call
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a trailblazing company in the field of dermatology therapeutics, has announced it will host a conference call and live webcast at ...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical ...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin ...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing ...
Verrica Pharmaceuticals Inc VRCA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
Fourth Quarter Revenue: Verrica Pharmaceuticals Inc (NASDAQ:VRCA) reported YCANTH revenue of $1.9 million. Full-Year Revenue: Full-year revenue for YCANTH totaled $4.7 million. Insurance Coverage ...
Loading the latest forecasts...